Evoke Pharma Inc (EVOK) - Long-Term Debt to Capital Coefficient
Evoke Pharma, Inc. (EVOK) generates revenue from an innovative nasal treatment for diabetic gastroparesis, whose specific application ensures customer loyalty and a steady cash flow. Meanwhile, the business is implementing eco-friendly packaging and safe synthesis methods. This price chart reflects a value of 0.01. High product margins allow the company to reduce the impact of fixed logistics and promotion costs as sales volumes grow.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261031&filename=GURU_Markets_-_EVOK_-_Evoke-Pharma-Inc._-_Long-Term-Debt-to-Capital "EVOK: Evoke Pharma Long-Term Debt to Capital 07/04/2022 - 12/27/2025 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Evoke Pharma, Inc. (EVOK)
Professional capital assesses the financial stability of the issuer through its liability structure. This long-term debt-to-net assets ratio compares loans with maturities exceeding one year against the market value of equity. Rising leverage increases interest expenses, creating risks during rate hikes. For Evoke Pharma, Inc. (EVOK), this is critical when scaling sales of the Gimoti spray. Low reliance on borrowed funds confirms the asset's reliability.